A continuación encontrarás una serie de artículos que podrían ser de tu interés. Puedes visualizarlos a través de los siguientes accesos.

Si quieres consultar algún artículo que no encuentres en este listado, indícanoslo haciendo click aquí:




Age Demographics of Subjects Enrolled in Global, Interventional Phase 3 Melanoma Clinical Trials


Independent evaluation of melanoma polygenic risk scores in UK and Australian prospective cohorts


COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States




Retrospective Analysis of Safety in Elderly BRAF V600 mutation-positive Advanced Melanoma Patients treated with Dabrafenib (D) and Trametinib (T) and Correlation with Non-elderly Patients


Analysis of pirexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials


Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastasic and adjuvant setting




External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?


Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma


Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma




Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF V600E or BRAF V600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial


Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma


Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology




Dabrafenib plus trametinib in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial


Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial


Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib



Valora este contenido: 
todavía no hay valoraciones

Ask Speakers


Medical Information Request